Thera-SAbDab

PANITUMUMAB

>   Structural Summary
TherapeuticPanitumumab
TargetEGFR
Heavy ChainQVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK
100% seqID Fv Structure5sx4 [Fvs: HL, JI], 5sx5 [Fvs: HL, JK]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2004
INN Year Recommended2005
Companies InvolvedAmgen, Grupo Espanol Multidisciplinario del Cancer Digestivo, Netherlands Cancer Institute, Novartis, Takeda, University of Texas M. D. Anderson Cancer Center, Wissenschaftlicher Service Pharma
Conditions ApprovedColorectal cancer
Conditions ActiveAnal cancer, Bladder cancer, Breast cancer, Gastric cancer, Neuroendocrine tumours, Oesophageal cancer, Rectal cancer
Conditions DiscontinuedHead and neck cancer, Malignant melanoma, Prostate cancer, Renal cell carcinoma, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]